Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'

N. Homer, D. S. Grewal, R. G. Mirza, A. T. Lyon, M. K. Gill

Research output: Contribution to journal › Letter › peer-review

Fingerprint

Dive into the research topics of 'Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results''. Together they form a unique fingerprint.